

**Virginia Medicaid Preferred Drug List (PDL) Program:  
Annual Review of PDL Phase II and Review of New Drugs  
Pharmacy and Therapeutics Committee Meeting  
Tuesday, April 17, 2007  
9:00 a.m., 7<sup>th</sup> Floor Conference Rooms  
**DRAFT AGENDA****

**Welcome and Comments from  
DMAS' Director**

**Patrick Finnerty,  
DMAS Director**

**Comments from the Chairperson**

**Randy Axelrod, M.D.,  
Chairman**

**Acceptance of Minutes From  
October 23, 2006 P&T Meeting**

**P&T Committee Members**

**Review of Proton Pump Inhibitors  
(PPI) Drug Class**

**Randy Axelrod, M.D.,  
Chairman**

**Drug Class Discussions**

**P&T Committee Members**

**Review of New Drugs in PDL Phase I**

- Coreg CR - Beta Blockers
- Oxybutynin Chloride ER – Urinary Tract Antispasmodics

**Phase II PDL Annual Review**

***Diabetes - Oral Hypoglycemics***

- Second Generation Sulfonylureas
- Alpha-Glucosidase Inhibitors
- Biguanides,
- Biguanide Combination Products
- Meglitinides
- Thiazolidinediones)

***Asthma/allergy***

- Leukotriene Modifiers

***Analgesics***

- Non-Steroidal Anti- Inflammatory Drugs (NSAID) (*now includes Cox-2 Inhibitors*)
- Long Acting Narcotics

***Central Nervous System***

- Antihyperkinesia/CNS Stimulants (Medications for ADD/ADHD)

***Osteoporosis***

- Bisphosphonates

***Antibiotics/Anti-Infectives***

- Second Generation Cephalosporins
- Third Generation Cephalosporins

- Second Generation Quinolones Systemic
- Third Generation Quinolones – Systemic
- Macrolides - Adult and Pediatric
- Oral Antifungals for Onychomycosis

***Antivirals***

- Herpes
- Influenza

***Ophthalmic***

- Alpha-2 Adrenergic
- Beta-blockers
- Carbonic Anhydrase Inhibitors
- Prostaglandin Inhibitors
- Anti-Inflammatory
- Quinolones
- Antihistamines
- Mast Cell Stabilizers

***Miscellaneous***

- Serotonin Receptor Agonists (Triptans)

## Confidential Meeting

Confidential Meeting for  
P&T Committee Members,  
DMAS, and FHSC Pursuant to  
42 U.S.C. § 1396r-8 to discuss  
pricing information

### Criteria Discussion of Phase I New Drugs\*

P&T Committee Members

### Criteria Discussions for PDL Phase II Drug Classes\*

P&T Committee Members

### Next Meeting – TBD

Randy Axelrod, M.D.,  
Chairman

*\*Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions*

**Oral presentations:** The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on ***only*** the drug classes subject to PDL Phase II annual review and specific new drugs in PDL Phase I classes listed on the Agenda. All presentations must include newly published information (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:

- PDL Phase II Annual Review – March 2006 to present
- New Drugs in PDL Phase I Drug Classes – October 2005 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. Speakers must receive a confirmation number to verify the presentation is scheduled.

If you are interested in providing specific clinical information to the Committee at the meeting, please submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to [pdlinput@dmass.virginia.gov](mailto:pdlinput@dmass.virginia.gov) by COB Tuesday, March 27, 2007.

**Written information/comments:** The P&T Committee will also accept written comments for consideration. Please send statements to [pdlinput@dmass.virginia.gov](mailto:pdlinput@dmass.virginia.gov) by COB Tuesday, March 27, 2007.